These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 16763586)

  • 1. A special biotech speculation.
    Jacobs T
    Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
    [No Abstract]   [Full Text] [Related]  

  • 2. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 3. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 4. The protection racket.
    Jacobs T
    Nat Biotechnol; 2006 Sep; 24(9):1081. PubMed ID: 16964213
    [No Abstract]   [Full Text] [Related]  

  • 5. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 6. No pain, no gain?
    Jacobs T
    Nat Biotechnol; 2005 Aug; 23(8):934. PubMed ID: 16082357
    [No Abstract]   [Full Text] [Related]  

  • 7. Beware the biotech barker.
    Jacobs T
    Nat Biotechnol; 2005 May; 23(5):538. PubMed ID: 15877065
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech IPOs: handle with care.
    Jacobs T
    Nat Biotechnol; 2003 Dec; 21(12):1437. PubMed ID: 14647322
    [No Abstract]   [Full Text] [Related]  

  • 9. Paying over the odds.
    Jacobs T
    Nat Biotechnol; 2006 Jan; 24(1):29. PubMed ID: 16404388
    [No Abstract]   [Full Text] [Related]  

  • 10. More than meets the eyes?
    Jacobs T
    Nat Biotechnol; 2004 Oct; 22(10):1221. PubMed ID: 15470455
    [No Abstract]   [Full Text] [Related]  

  • 11. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 12. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 13. Another clue to biotech value.
    Jacobs T
    Nat Biotechnol; 2003 Jul; 21(7):746. PubMed ID: 12833091
    [No Abstract]   [Full Text] [Related]  

  • 14. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 15. Divining the path to a successful European exit.
    Buch HK; Gustafsson AC; Drvota V; Sundberg CJ
    Nat Biotechnol; 2011 Mar; 29(3):205-7. PubMed ID: 21510008
    [No Abstract]   [Full Text] [Related]  

  • 16. My worst biotech investment.
    Jacobs T
    Nat Biotechnol; 2006 Apr; 24(4):401. PubMed ID: 16601718
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech holds steady in Q4.
    Mitchell P
    Nat Biotechnol; 2004 Feb; 22(2):135-6. PubMed ID: 14755275
    [No Abstract]   [Full Text] [Related]  

  • 18. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotechs for pennies?
    Jacobs T
    Nat Biotechnol; 2004 Dec; 22(12):1509. PubMed ID: 15583652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.